quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:02:32·13d
PRRelease
Replimune Group Inc. logo

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

REPL· Replimune Group Inc.
Health Care
Original source

Companies

  • REPL
    Replimune Group Inc.
    Health Care

Recent analyst ratings

  • Apr 13UpdateBMO Capital Markets$1.00
  • Apr 13UpdateJefferies$2.00
  • Apr 13UpdateAnalyst-
  • Apr 13UpdateH.C. Wainwright-
  • Apr 13UpdateLeerink Partners$2.00
  • Apr 13UpdateWedbush$2.00

Related

  • ANALYST10d
    Replimune downgraded by BMO Capital Markets with a new price target
  • ANALYST10d
    Replimune downgraded by Jefferies with a new price target
  • ANALYST10d
    Replimune downgraded by Analyst
  • ANALYST10d
    Replimune downgraded by H.C. Wainwright
  • ANALYST10d
    Replimune downgraded by Leerink Partners with a new price target
  • ANALYST10d
    Replimune downgraded by Wedbush with a new price target
  • SEC13d
    Replimune Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  • PR13d
    Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022